15α-Hydroxy-9-ketoprostansaeure | 37786-01-9

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 15α-Hydroxy-9-ketoprostansaeure
• 英文别名: AY 23626；(-)-(S)-15-hydroxy-9-oxo-prostanoic acid；11-deoxy-13,14-dihydro-prostaglandin E1；Prostan-1-oic acid, 15-hydroxy-9-oxo-, (15S)-；7-[(1R,2S)-2-[(3S)-3-hydroxyoctyl]-5-oxocyclopentyl]heptanoic acid
• CAS: 37786-01-9
• 化学式: C₂₀H₃₆O₄
• 分子量: 340.503
• InChiKey: POFQOMOFTOFTNO-OKZBNKHCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  24
• 可旋转键数：
  14
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  74.6
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• REMEDY FOR CARTILAGE-RELATED DISEASES
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：EP1661580A1

  公开（公告）日：2006-05-31

  The present invention relates an agent for treating cartilage-related disease comprising as an active ingredient a substance having an EP2 and/or EP3 agonist activity. A substance having an agonist activity to EP2 and/or EP3 has effects of stimulating chondrogenesis, stimulating chondrocyte growth, stimulating chondrocyte differentiation, inhibiting cartilage calcification and inhibiting cartilage degradation, or effects of stimulating integrin mRNA expression, stimulating fibronectin mRNA expression, stimulating D1 mRNA expression and inhibiting osteopontin mRNA expression, and, therefore, is useful as an agent for treating cartilage-related disease.

  本发明涉及一种治疗软骨相关疾病的制剂，其活性成分包括一种具有 EP2 和/或 EP3 激动剂活性的物质。具有 EP2 和/或 EP3 激动剂活性的物质具有刺激软骨生成、刺激软骨细胞生长、刺激软骨细胞分化、抑制软骨钙化和抑制软骨降解的作用，或具有刺激整合素 mRNA 表达、刺激纤连蛋白 mRNA 表达、刺激 D1 mRNA 表达和抑制骨生成素 mRNA 表达的作用，因此可用作治疗软骨相关疾病的制剂。
• Remedy for cartilage-related diseases
  申请人：Ono Pharmaceutical Co., Ltd.

  公开号：EP2422814A1

  公开（公告）日：2012-02-29

  A remedy for cartilage-related diseases containing as the active ingredient a substance having an agonistic activity to EP2 and/or EP3. A substance having an agonistic activity to EP2 and/or EP3 has effects of promoting chondrogenesis, promoting chondrocyte growth, promoting chondrocyte differentiation, inhibiting cartilage calcification and inhibiting cartilage degradation, or effects of promoting integrin mRNA expression, promoting fibronectin mRNA expression, promoting cyclin D1 mRNA expression and inhibiting osteopontin mRNA expression, and therefore, is useful as a remedy for cartilage-related diseases.

  一种治疗软骨相关疾病的药物，其活性成分含有一种对 EP2 和/或 EP3 具有激动活性的物质。对 EP2 和/或 EP3 具有激动活性的物质具有促进软骨生成、促进软骨细胞生长、促进软骨细胞分化、抑制软骨钙化和抑制软骨降解的作用，或具有促进整合素 mRNA 表达、促进纤连蛋白 mRNA 表达、促进细胞周期蛋白 D1 mRNA 表达和抑制骨生成素 mRNA 表达的作用，因此可作为软骨相关疾病的治疗药物。
• Remedy for Cartilage-Related Diseases
  申请人：Toguchida Junya

  公开号：US20070270489A1

  公开（公告）日：2007-11-22

  The present invention relates an agent for treating cartilage-related disease comprising as an active ingredient a substance having an EP2 and/or EP3 agonist activity. A substance having an agonist activity to EP2 and/or EP3 has effects of stimulating chondrogenesis, stimulating chondrocyte growth, stimulating chondrocyte differentiation, inhibiting cartilage calcification and inhibiting cartilage degradation, or effects of stimulating integrin mRNA expression, stimulating fibronectin mRNA expression, stimulating D1 mRNA expression and inhibiting osteopontin mRNA expression, and, therefore, is useful as an agent for treating cartilage-related disease.
• DIFLUOROLACTAM COMPOSITIONS FOR EP4-MEDIATED OSTEO RELATED DISEASES AND CONDTIONS
  申请人：Cayman Chemical Company, Inc.

  公开号：US20170260173A1

  公开（公告）日：2017-09-14

  Disclosed herein are compositions and methods of treating osteroporosis, bone fracture, bone loss, and increasing bone density by administration of compounds of formula (I) or compositions comprising a compound of formula (I) and a pharmaceutically acceptable carrier, wherein L 1 , L 2 , L 4 , R 1 , R 4 , R 5 , R 6 , and s are as defined in the specification.
• US3932463A
  申请人：——

  公开号：US3932463A

  公开（公告）日：1976-01-13